Serum Insulin-Like Growth Factor-I, Insulin-Like Growth Factor Binding Proteins, and Bone Mineral Content in Hyperthyroidism
Authors:
- Peter LakatosPLPeter Lakatos
- Janos FoldesJFJanos Foldes
- Zsolt NagyZNZsolt Nagy
- Istvan TakacsITIstvan Takacs
- Gabor SpeerGSGabor Speer
- Csaba HorvathCHCsaba Horvath
- Subburaman MohanSMSubburaman Mohan
- David J. BaylinkDBDavid J. Baylink
- Paula H. SternPSPaula H. Stern
- 1 May 2000
- journal article
- research article
- Published by SAGE Publications in Thyroid®
- Vol. 10 (5) , 417-423
Abstract
The mechanism by which thyroid hormones promote bone growth has not yet been elucidated. In vitro, thyroid hormones stimulate insulin-like growth factor-I (IGF-I) production by osteoblasts, which is important for the anabolic effects of the hormone on bone. To determine whether the IGF-I/IGF binding protein (IGFBP) profile is affected when thyroid hormone production is altered in vivo, we studied 36 women who had recently been diagnosed with hyperthyroidism (age: 29-67 years; 19 with Graves' disease, 17 with toxic nodular goiter) and 36 age-matched healthy women as controls. Serum IGF-I, and its binding proteins (IGFBP-3, IGFBP-4, and IGFBP-5), as well as bone mineral density (BMD) at the lumbar spine, femoral neck, and radius midshaft were measured before and 1 year after antithyroid (methimazole) treatment. Serum IGF-I levels were significantly increased in the hyperthyroid patients before treatment (214 ± 18.2 ng/mL vs. 145 ± 21.3 ng/mL; p < 0.05). There was no difference in IGF-I levels of patients with Graves' disease and toxic nodular goiter. Serum IGF-I concentrations returned to normal after treatment with methimazole. Serum IGFBP-3 and IGFBP-4 values were significantly elevated in the hyperthyroid group before treatment (3960 ± 220 ng/mL and 749.7 ± 53.1 ng/mL vs. 2701 ± 180 ng/mL and 489.9 ± 32.4 ng/mL; p < 0.05 and p < 0.01, respectively) and were reduced to those of controls after treatment. Serum IGFBP-5 of hyperthyroid subjects was not different from that of controls either before or after therapy. Serum free thyroxine showed a positive correlation with serum levels of IGF-I (r = 0.73, p < 0.05), IGFBP-3 (r = 0.59, p < 0.05), and IGFBP-4 (r = 0.67, p < 0.05) but not IGFBP-5. BMD at the radius midshaft was significantly lower in hyperthyroid patients at the start of the study and showed a positive correlation with serum IGF-I (r = 0.58; p < 0.001) and a negative correlation with IGFBP-4 (r = -0.61; p < 0.05). Radius BMD showed a 7.2% increase in the hyperthyroid group after 1 year of methimazole treatment, and the correlation between BMD and serum IGF-I disappeared. Our data indicate that thyroid hormones may influence the IGF-I/IGFBP system in vivo in hyperthyroidism. The anabolic effects of increased levels of IGF-I may be limited in hyperthyroidism due to the increases of inhibitory IGFBPs that can counteract the anabolic effects and contribute to the observed net bone loss.Keywords
This publication has 19 references indexed in Scilit:
- Positive association between circulating free thyroxine and insulin‐like growth factor I concentrations in euthyroid elderly individualsClinical Endocrinology, 1998
- Serum Levels of Insulin-like Growth Factor (IGF) I, IGF-Binding Protein (IGFBP)-2, and IGFBP-3 in Osteoporotic Patients with and without Spinal FracturesJournal of Bone and Mineral Research, 1997
- Low circulating IGF-I levels in hyperthyroidism are associated with decreased GH response to GH-releasing hormoneClinical Endocrinology, 1995
- Hormonal control of insulin-like growth factor-I and growth hormone receptor mRNA expression by porcine hepatocytes in cultureJournal of Endocrinology, 1995
- Age-related changes in IGFBP-4 and IGFBP-5 levels in human serum and bone: Implications for bone loss with agingProgress in Growth Factor Research, 1995
- Thyroid hormones increase insulin‐like growth factor mRNA levels in the clonal osteoblastic cell line MC3T3‐E1FEBS Letters, 1994
- Isolation of a novel insulin-like growth factor (IGF) binding protein from human bone: A potential candidate for fixing IGF-II in human boneBiochemical and Biophysical Research Communications, 1991
- The biphasic effect of triiodothyronine compared to bone resorbing effect of PTH on bone modelling of mouse long bone in vitroBone, 1990
- OSTEOPOROSIS AND FRACTURES FOLLOWING THYROTOXICOSISThe Lancet, 1971
- ACCELERATED SKELETAL DEVELOPMENT FROM THYROTOXICOSIS AND THYROID OVERDOSAGE IN CHILDHOODThe Lancet, 1951